Burns J W & Co. Inc. NY Sells 2,713 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Burns J W & Co. Inc. NY reduced its position in Thermo Fisher Scientific by 19.8% in Q2, now owning 10,962 shares valued at approximately $4.45 million.
• Thermo Fisher's Q2 earnings exceeded analysts' expectations, reporting $5.36 earnings per share and a revenue of $10.86 billion.
• The company announced a quarterly dividend of $0.43, translating to an annualized amount of $1.72 and a dividend yield of 0.4%.

Burns J W & Co. Inc. NY lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 19.8% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,962 shares of the medical research company's stock after selling 2,713 shares during the quarter. Burns J W & Co. Inc. NY's holdings in Thermo Fisher Scientific were worth $4,445,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in TMO. GAMMA Investing LLC lifted its holdings in shares of Thermo Fisher Scientific by 60,610.9% during the first quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after buying an additional 2,415,346 shares during the last quarter. Nuveen LLC acquired a new position in shares of Thermo Fisher Scientific during the first quarter worth approximately $532,360,000. Sarasin & Partners LLP acquired a new position in shares of Thermo Fisher Scientific during the first quarter worth approximately $242,991,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $195,049,000. Finally, EdgePoint Investment Group Inc. acquired a new position in shares of Thermo Fisher Scientific during the first quarter worth approximately $172,139,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock traded down $1.08 during mid-day trading on Friday, hitting $480.02. 4,241,401 shares of the company were exchanged, compared to its average volume of 1,433,914. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The business has a fifty day moving average of $472.01 and a 200 day moving average of $449.50. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $623.77. The company has a market capitalization of $181.26 billion, a PE ratio of 27.76, a price-to-earnings-growth ratio of 2.56 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period in the prior year, the company posted $5.37 earnings per share. The business's revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. UBS Group upped their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday, July 24th. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the company an "outperform" rating in a research note on Tuesday, September 2nd. HSBC restated a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Raymond James Financial restated an "outperform" rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, William Blair began coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an "outperform" rating for the company. Sixteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $588.35.

Insider Transactions at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,066 shares of company stock worth $14,182,963. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.